Skip to main content
HitGen Inc. logo

HitGen Inc. — Investor Relations & Filings

Ticker · 688222 ISIN · CNE1000040G3 Shanghai Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 629 across all filing types
Latest filing 2022-05-31 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 688222

About HitGen Inc.

https://www.hitgen.com/en

HitGen Inc. is a technology-driven research and development organization focused on the discovery of novel small molecule drug candidates. The company leverages its proprietary DNA-encoded library (DEL) platform, which features a collection of over 1.2 trillion diverse small molecules, to enable efficient hit identification and lead optimization. HitGen offers integrated drug discovery services, incorporating fragment-based drug discovery (FBDD) and structure-based drug design through its specialized research facilities. Its core operations include collaborative research partnerships with global pharmaceutical entities and the development of an internal pipeline of therapeutic programs. The platform combines synthetic chemistry, biology, and data informatics to streamline the identification of bioactive compounds for complex therapeutic targets.

Recent filings

Filing Released Lang Actions
独立董事关于第二届董事会第一次会议相关议案的独立意见
Board/Management Information Classification · 95% confidence The document is a statement of independent opinions from independent directors regarding the nomination and election procedures for a board member candidate at a board meeting. It references the company's board meeting and governance rules but does not contain financial data, audit information, or detailed management reports. It is related to board/management information, specifically about board member nomination and approval. The document length is short and focused on governance matters, not an annual report or audit report. Therefore, the most appropriate classification is Board/Management Information (MANG).
2022-05-31 Chinese
上海证券交易所《关于成都先导药物开发股份有限公司2021年年度报告的信息披露监管问询函》
Regulatory Filings Classification · 95% confidence The document is a regulatory inquiry letter from the Shanghai Stock Exchange regarding the company's 2021 Annual Report. It requests additional disclosures and clarifications about the annual report's content, including financial data, business operations, acquisitions, and fundraising projects. The document is not the annual report itself but a regulatory follow-up or request for supplementary information related to the annual report. The document length is 2930 characters, which is relatively short and consistent with a regulatory inquiry letter rather than a full report. Therefore, this document fits best under Regulatory Filings (RNS) as it is a regulatory communication and not the report itself.
2022-05-31 Chinese
独立董事提名人声明（薛军福）
Board/Management Information Classification · 100% confidence The document is a nomination statement for an independent director candidate for the board of Chengdu Lead Drug Development Co., Ltd. It details the qualifications, independence criteria, and compliance with regulatory requirements for the nominee. There is no financial data, no report or announcement of financial results, no voting results, no legal proceedings, or other typical financial or regulatory filings. This document is related to board/management information, specifically about a board member nomination. Therefore, the appropriate classification is Board/Management Information (MANG). The document length is short and it is not an announcement of a report but a standalone statement about board nomination.
2022-05-31 Chinese
成都先导药物开发股份有限公司关于修订《公司章程》的公告
Governance Information Classification · 95% confidence The document is an announcement regarding the revision of the company's Articles of Association (公司章程). It details changes to the board composition and governance structure, referencing relevant laws and regulations. The document is not a full report but an announcement of governance changes requiring shareholder approval. It does not contain financial data or detailed management discussion. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules, board structure, and governance practices. The document length is short and focused on governance amendments, not a full report or regulatory filing.
2022-05-31 Chinese
中国国际金融股份有限公司关于成都先导药物开发股份有限公司2021年年度报告的信息披露监管问询函的专项核查意见
Management Reports Classification · 95% confidence The document is a detailed response to regulatory inquiries regarding the 2021 annual report of Chengdu Lead Pharma Co., Ltd. It discusses financial data, revenue, costs, business segments, client concentration, and sustainability of income streams. The text references the 2021 annual report multiple times and provides extensive financial and operational analysis related to that fiscal year. The document is lengthy (15,000 characters) and contains substantive financial data and management explanations, not merely an announcement or certification. It is not a transcript, proxy, or other specific filing type but rather a detailed management discussion and analysis related to the annual report. Therefore, the best fitting category is Management Reports (MDA).
2022-05-31 Chinese
关于选举第二届监事会职工代表监事的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the election of a new employee representative supervisor to the company's supervisory board. It includes details about the election process, compliance with relevant laws and regulations, and the biography of the elected individual. There is no financial data, no mention of financial results, no report attached or referenced, and no indication of a meeting presentation or voting results from a general meeting. This fits the category of Board/Management Information (MANG), as it concerns changes in the company's supervisory board members.
2022-05-29 Chinese

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.